AstraZeneca (AZN) CEO granted 18,359 shares as performance award vests

Rhea-AI Filing Summary

AstraZeneca PLC reported that an award of ordinary shares under the AstraZeneca Performance Share Plan vested to Chief Executive Officer Pascal Soriot on 14 May 2026. The award, originally granted on 14 May 2021, was subject to performance measures over three years followed by a two-year holding period.

Application of these performance measures resulted in 88% of the award vesting, with the remainder lapsing. After dividend reinvestment and tax withholding, Mr Soriot acquired 18,359 ordinary shares for nil consideration, changing his beneficial interests in AstraZeneca shares. The fair market value at vest for tax purposes was 13,766 pence per share.

Key Figures

Shares acquired: 18,359 shares Vesting percentage: 88% Fair market value at vest: 13,766 pence per share +2 more

5 metrics

Shares acquired 18,359 shares Ordinary shares acquired by CEO under AZPSP on 14 May 2026

Vesting percentage 88% Portion of AstraZeneca Performance Share Plan award that vested

Fair market value at vest 13,766 pence per share Closing price on London Stock Exchange for tax purposes at vest

Award grant date 14 May 2021 Grant date of AZPSP award to Pascal Soriot

Performance period length 3 years Performance measurement period before two-year holding period

Key Terms

AstraZeneca Performance Share Plan, person discharging managerial responsibilities, EU Market Abuse Regulation, holding period, +1 more

5 terms

AstraZeneca Performance Share Plan financial

"an award of the Company's ordinary shares ... under the terms of the AstraZeneca Performance Share Plan (AZPSP)"

person discharging managerial responsibilities regulatory

"18 May 2026 Transaction by Person Discharging Managerial Responsibilities"

A person discharging managerial responsibilities is an individual who holds a senior role with authority to make or influence a company’s strategic or operational decisions, such as executives, board members, or other top managers. Investors care because these people often have access to confidential information and their buying or selling of company shares must be disclosed—like a referee who knows the score before the crowd, their actions can signal important, non-public insights about a company's prospects.

EU Market Abuse Regulation regulatory

"notification, made in accordance with the requirements of the EU Market Abuse Regulation"

A set of EU-wide rules that prevent cheating in financial markets by banning insider trading, market manipulation, and misleading disclosure; it also requires timely public release of key company information so everyone can play on a level field. For investors, it reduces the risk that prices are driven by secret deals or false signals, making markets fairer and more reliable for deciding when to buy or sell — like referees enforcing fair play in a game.

holding period financial

"On the third anniversary of grant the award was placed in a two-year holding period."

nil consideration financial

"Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration."

Form 6-K: How Foreign Companies Report to the SEC →

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of May 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Director/PDMR Shareholding

18 May 2026

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 14 May 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP).

The AZPSP award was granted on 14 May 2021 as part of the award granted to Mr Soriot on 5 March 2021, and reflected the revised limits of the AZPSP, as approved by shareholders at the Company's 2021 Annual General Meeting. The award was subject to a combination of performance measures focused on scientific, commercial, financial and sustainability performance, assessed over a three-year performance period. On the third anniversary of grant the award was placed in a two-year holding period. The award vested at the end of that holding period. Application of the performance measures specified at the time of grant resulted in 88% of the AZPSP award vesting and the remaining unvested part lapsing.

Following the reinvestment of dividends accrued during performance and holding periods of the AZPSP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Soriot's beneficial interests in Ordinary Shares changed as detailed in the table below:

PDMR	Ordinary Shares acquired under the AZPSP
Pascal Soriot	18,359

For tax purposes, the fair market value of an Ordinary Share at vest of the AZPSP award was 13,766 pence, being the closing price on the London Stock Exchange on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Pascal Soriot
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		0	18,359
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	14 May 2026
f)	Place of the transaction	Outside a trading venue

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 18 May 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What did AstraZeneca (AZN) announce in this Form 6-K?

AstraZeneca announced that a performance share award granted to CEO Pascal Soriot under the AstraZeneca Performance Share Plan vested on 14 May 2026, resulting in his acquisition of 18,359 ordinary shares for nil consideration after performance testing, dividend reinvestment, and tax withholding.

How many AstraZeneca (AZN) shares did the CEO receive on vesting?

Pascal Soriot acquired 18,359 AstraZeneca ordinary shares when his AstraZeneca Performance Share Plan award vested. These shares were delivered after applying performance conditions, reinvesting dividends accrued during the award period, and withholding a portion of shares to meet tax obligations arising on vesting.

What percentage of Pascal Soriot’s AstraZeneca Performance Share Plan award vested?

88% of Pascal Soriot’s AstraZeneca Performance Share Plan award vested. The remaining part of the award lapsed after performance measures focused on scientific, commercial, financial, and sustainability outcomes were assessed over a three-year period, followed by a two-year holding period before final vesting.

What was the fair market value used for AstraZeneca (AZN) tax purposes at vesting?

For tax purposes, the fair market value of an AstraZeneca ordinary share at vest was 13,766 pence. This value was based on the closing price on the London Stock Exchange on the last trading day before the vesting date of 14 May 2026.

What is the nature of the CEO’s AstraZeneca share transaction disclosed here?

The CEO’s transaction was an acquisition of ordinary shares pursuant to the vesting of an AstraZeneca Performance Share Plan award, for nil consideration. It was a single transaction conducted outside a trading venue, reflecting compensation rather than an open-market share purchase or sale.

Which regulation governs this AstraZeneca (AZN) PDMR notification?

The notification regarding Pascal Soriot’s share award vesting was made in accordance with the requirements of the EU Market Abuse Regulation, as it forms part of UK law under the European Union (Withdrawal) Act 2018, governing disclosures by persons discharging managerial responsibilities.